Cold plasma treatment of in vitro gliomas and patient-derived tumors – Role of human myeloid cells

Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Sascha Marx, Frederik Kinnen, Juliane Moritz, Eric Freund, Mathias Stope, Sandra Bien-Möller, Bernhard H. Rauch, Christopher Ritter, Henry W.S. Schroeder, Sander Bekeschus Tumor-associated macrophages (TAM) are the pre-dominant myeloid cells within malignant glioma and are a poor prognostic factor in patients. TAM in malignant glioma show a tumor-supporting, so-called M2 phenotype. The aim of this study was to characterize phenotype and relevant markers of monocytes/macrophages in the tumor microenvironment following exposure to cold physical plasma Monocytes were enriched from peripheral blood mononuclear cells derived from young healthy volunteers donating blood after informed consent and in accordance with the guidelines of the local ethics committee. Monocytes were co-cultured with a glioma cell line (U87MG). The latter readily induced a M2 phenotype in these monocytes as seen by an increase in CD163 expression. Prior to co-culture, either U87MG cells or monocytes were treated with an atmospheric pressure argon plasma jet (kINPen) for 15 seconds or 5 seconds, respectively. Non-treated co-cultures as well as single monocytes cultures served as controls. FACS immuno-phenotyping of monocytes/macrophages was performed for CD55, CD97, CD162, CD163, CD169, CD204, CD276, HLA-DR, and HLA-ABC after 24h, 48h, and 72h. M2 polarization of monocytes by U87MG was neither attenu...
Source: Clinical Plasma Medicine - Category: Research Source Type: research